CpG Methylation Detection via Bisulfite Conversion and Segmented Amplification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting hypermethylated DNA in cancer diagnosis face challenges due to high backgrounds of unmethylated DNA and limited sensitivity, especially when tumor DNA is scarce and fragmented, as seen in early-stage cancer where the DNA half-life is short.
Innovation Solution
A method involving the conversion of cytosine to uracil in DNA, followed by amplification using methylation-unspecific primer oligonucleotides and methylation-specific blockers, with a focus on reducing amplicon size to less than 100 bp to enhance sensitivity, and introducing mismatches at CpG or SNP sites to improve primer binding without compromising specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional amplification methods are used for detecting hypermethylated DNA, then the detection can be performed with standard protocols, but the sensitivity is insufficient when tumor DNA is scarce and fragmented
Solution Approach 1:
The patent divides the amplification process into two distinct stages: a first amplification step that generates initial copies, and a second amplification step that dramatically increases sensitivity. This segmentation allows the method to effectively amplify scarce tumor DNA fragments while maintaining specificity, resolving the contradiction between low DNA concentration and detection sensitivity
Solution Approach 2:
The patent employs parameter changes by using different primer concentrations, extension times, and temperature conditions in the first versus second amplification steps. These parameter optimizations enable the method to achieve superior sensitivity for fragmented tumor DNA compared to conventional single-step amplification
2Measurement precision
If the amplicon size is reduced to less than 100 bp to enhance sensitivity, then detection sensitivity improves, but the complexity of primer design and optimization increases
Solution Approach 1:
The patent segments the detection process into two amplification steps, each with optimized primers designed for short amplicons (<100 bp). This segmentation allows use of simplified short-primer strategies in both steps, making the overall complex process manageable while achieving high sensitivity
Solution Approach 2:
The first amplification step performs preliminary amplification that enriches the template for the second step. This preliminary action allows the use of simplified short amplicon design in both steps while still achieving high sensitivity, as the first step pre-concentrates the target
3Productivity
If mismatches are introduced at CpG or SNP sites to improve primer binding, then amplification efficiency increases, but the risk of reducing specificity increases
Solution Approach 1:
The patent applies local quality by introducing mismatches at specific positions within the primer sequences rather than uniformly throughout. This localized mismatch strategy enhances binding efficiency at critical regions while maintaining specificity through careful position selection, resolving the contradiction between productivity and reliability
Solution Approach 2:
The patent uses parameter changes by optimizing the position, type, and number of mismatches in primers based on empirical data. These controlled parameter modifications improve amplification efficiency while maintaining specificity, as the mismatches are strategically placed to enhance binding without causing non-specific amplification
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves the detection of hypermethylated DNA, allowing for earlier cancer diagnosis by enhancing signal sensitivity and specificity, even in low concentrations of tumor DNA amidst high background noise.
Implementation Method 1
converting, in the DNA, cytosine unmethylated in the 5-position to uracil or another base that does not hybridize to guanine
Data Source
AI summary
The present invention relates to the field of pharmacogenomics and in particular to detecting the presence or absence of hypermethylated DNA. The detection of CpG methylation in marker DNA is useful for the diagnosis of cancers and the invention provides improved methods for this purpose. These improved methods allow in particular for a more sensitive detection of methylated marker DNA with high backgrounds of unmethylated marker DNA.